Clin2
NCT06582017Possibly a fitRecruiting

Study of QXL138AM for advanced solid tumors and multiple myeloma

Ovarian CancerPancreas CancerUrothelial CarcinomaRenal Cell CarcinomaHepatocellular CarcinomaGastrointestinal CancerLung CancerProstate Cancer

Part of Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.

This trial tests an investigational drug called QXL138AM for people with advanced solid tumors or multiple myeloma that has not responded to standard treatments. The goal is to see if the drug is safe and effective.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
100 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You must have one of these cancers: ovarian, pancreatic, urothelial, renal, hepatocellular, GI, lung, prostate, breast, or multiple myeloma.
  • You must have tried standard treatments and they stopped working, or they are not suitable for you.
  • You must be 18 years or older.
  • You must be able to care for yourself (ECOG score of 0, 1, or 2).
  • You must have a measurable tumor or evaluable disease (for myeloma patients, specific criteria apply).
  • You must have good organ function and heart health, and agree to use effective birth control if applicable.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07670312Not yet recruiting· Phase 1/Phase 2
Testing XYA02 for advanced solid tumors

This study tests an experimental drug called XYA02 for people with advanced solid tumors (like lung, ovarian, stomach, colorectal, or pancreatic cancer) that have come back or not responded to other treatments. The goal is to see if XYA02 can shrink tumors or slow their growth, and to find the best dose.

Sydney, New South Wales
NCT07453394Not yet recruiting· Phase 1/Phase 2
QLS5132 combination therapy for advanced solid tumors

This trial tests a new drug called QLS5132, alone or in combination, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it can shrink tumors or slow their growth.

NCT06823609Recruiting· Phase 1
Study of QLS-1304 for advanced solid tumors

This trial tests an experimental drug, QLS-1304, for people with advanced solid tumors that have stopped responding to standard treatment. The goal is to see if the drug is safe and effective.

Shanghai
NCT07462442Not yet recruiting· Phase 1
Study of QLS5308 for advanced solid tumors

This trial tests an investigational drug called QLS5308 for people with advanced solid tumors that have not responded to standard treatments. The study's goal is to find a safe dose and see how well it works.

NCT06932094Not yet recruiting· Phase 1
Testing QLS5132 for advanced solid tumors

This trial tests a new drug, QLS5132, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if the drug is safe and effective.

Hangzhou
NCT07256782Recruiting· Phase 1/Phase 2
A study of QLC5508 combinations for advanced solid tumors

This trial tests a new drug called QLC5508, given in combination with other treatments, for people with advanced solid tumors that have stopped responding to standard therapy or who haven't had treatment yet. The goal is to see if the combination can shrink tumors or slow their growth.

Shanghai

Hear when a new Ovarian cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.